Renub

    Cervical Cancer Test Market & Patients - Pap Smear, HPV DNA, VIA - Test & Patients - Worldwide

    Excel: 4 Hours
    PDF: 4 Hours
    Apr 2014
    Pages: 232

    Cervical Cancer Test Market Overview

    Cervical cancer is one of the deadliest cancers among woman all over the world. However in the past few decades, mortality from cervical cancer has significantly decreased in developed countries due to widely use of Pap smear test. HPV DNA and VIA test are other popular tests used across world. VIA test is most adoptable test in developing countries as it is cheaper in comparison to Pap smear test and HPV DNA test.

    Cervical cancer test market is dominated by United States in 2013. Germany and United Kingdom are other top two leaders in this market place. In Asian region, China and India are top two countries having largest cervical cancer test population. Few countries have also shown a decline in cervical cancer test market. However VIA test market accounts for largest share in cervical cancer test market in the case of developing countries like India and China.

    A high prevalence of HPV-infected patients across the globe, rising incidences of teenage sexual cases, a rising number of organized cervical cancer programs initiated by governments and NGOs and introduction of low cost VIA test are some of the major growth drivers for the cervical cancer test market. However, lack of insufficient healthcare infrastructure and lack of cervical cancer screening awareness are the major hinder for cervical testing market.

    Renub Research report titled "Cervical Cancer Test Market & Patients - Pap Smear, HPV DNA, VIA – Test & Patients – Worldwide” provides a comprehensive analysis of the current state of this market and likely future evolution over the next 5 years. This 232 page report with 240 Figures and 14 Table provides a complete analysis of top 20 Countries Cervical Cancer Test Market & Population. All the 20 countries in the report have been studied from 3 viewpoints.

    1. Cervical cancer Test Population (2007-2020)
     
         •  Pap smear test population (2007-2020)
         •  HPV DNA test population (2007-2020)
         •  VIA test Population (2007-2020)

    2. Cervical Cancer Mortality Population (2001-2011)

    3. Cervical Cancer Test Market (2007-2020)
     
        •  Pap smear test market (2007-2020)
        •  HPV DNA test market (2007-2020)
        •  VIA test market (2007-2020)

    All the 20 Countries studied in the report are as follows

    1. United Kingdom
    2. France
    3. Germany
    4. Italy
    5. Spain
    6. Sweden
    7. Switzerland
    8. Norway
    9. Netherlands
    10. United States
    11. Canada
    12. Japan
    13. Korea
    14. Singapore
    15. Malaysia
    16. Australia
    17. India
    18. China
    19. Thailand
    20. Indonesia

    Data Sources 

    This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by Renub Research team of industry experts.
     
    Primary sources include industry surveys and telephone interviews with industry experts. 

    Secondary sources information and data has been collected from various printable and non-printable sources like search engines, News websites, Government Websites, Trade Journals, White papers, Government Agencies, Magazines, Newspapers, Trade associations, Books, Industry Portals, Industry Associations and access to more than 500 paid databases. 

    1. Executive Summary

    2. Worldwide Cervical Cancer Test (Screening) Population & Forecast

    3. Worldwide Cervical Cancer Test (Screening) Market & Forecast
    3.1 Worldwide Cervical Cancer Pap Smear Test (Screening) Market & Forecast
    3.2 Worldwide Cervical Cancer HPV DNA Test (Screening) Market & Forecast
    3.3 Worldwide - Cervical Cancer Visual Inspection with Acetic Acid (VIA) Test (Screening) Market & Forecast

    4. Worldwide Cervical Cancer Test (Screening) Population Share, Market Share & Forecast
    4.1 Worldwide Cervical Cancer Test (Screening) Population Share & Forecast
    4.2 Worldwide Cervical Cancer Test (Screening) Market Share & Forecast
    4.3 Worldwide Cervical Cancer Pap Smear Test (Screening) Market Share & Forecast
    4.4 Worldwide Cervical Cancer HPV DNA Test (Screening) Market Share & Forecast
    4.5 Worldwide Cervical Cancer VIA Test (Screening) Market Share & Forecast

    5. United Kingdom – Cervical Cancer Test Analysis

    5.1 United Kingdom Cervical Cancer Test (Screening) Population
    5.1.1 United Kingdom Cervical Cancer Pap Smear Test Population & Forecast
    5.1.2 United Kingdom Cervical Cancer HPV DNA Test Population & Forecast

    5.2 United Kingdom Cervical Cancer Mortality

    5.3 United Kingdom Cervical Cancer Test (Screening) Analysis
    5.3.1 United Kingdom Cervical Cancer Test Market & Forecast
    5.3.2 United Kingdom Pap Smear Test Market & Forecast
    5.3.3 United Kingdom HPV DNA Test Market & Forecast

    6. France – Cervical Cancer Test Analysis
     
    6.1 France Cervical Cancer Test (Screening) Population
    6.1.1 France Cervical Cancer Pap Smear Test Population & Forecast
    6.1.2 France Cervical Cancer HPV DNA Test Population & Forecast

    6.2 France Cervical Cancer Mortality

    6.3 France Cervical Cancer Test (Screening) Analysis
    6.3.1 France Cervical Cancer Test Market & Forecast
    6.3.2 France Pap Smear Test Market & Forecast
    6.3.3 France HPV DNA Test Market & Forecast

    7. Germany – Cervical Cancer Test Analysis
     
    7.1 Germany Cervical Cancer Test (Screening) Population
    7.1.1 Germany Cervical Cancer Pap Smear Test Population & Forecast
    7.1.2 Germany Cervical Cancer HPV DNA Test Population & Forecast

    7.2 Germany Cervical Cancer Mortality

    7.3 Germany Cervical Cancer Test (Screening) Market
    7.3.1 Germany Cervical Cancer Test Market & Forecast
    7.3.2 Germany Pap Smear Test Market & Forecast
    7.3.3 Germany HPV DNA Test Market & Forecast

    8. Italy – Cervical Cancer Test Analysis
     
    8.1 Italy Cervical Cancer Test (Screening) Population
    8.1.1 Italy Cervical Cancer Pap Smear Test Population & Forecast
    8.1.2 Italy Cervical Cancer HPV DNA Test Population & Forecast

    8.2 Italy Cervical Cancer Mortality

    8.3 Italy Cervical Cancer Test (Screening) Market
    8.3.1 Italy Cervical Cancer Test Market & Forecast
    8.3.2 Italy Pap Smear Test Market & Forecast
    8.3.3 Italy HPV DNA Test Market & Forecast

    9. Spain – Cervical Cancer Test Analysis
     
    9.1 Spain Cervical Cancer Test (Screening) Population
    9.1.1 Spain Cervical Cancer Pap Smear Test Population & Forecast
    9.1.2 Spain Cervical Cancer HPV DNA Test Population & Forecast

    9.2 Spain Cervical Cancer Mortality

    9.3 Spain Cervical Cancer Test (Screening) Market
    9.3.1 Spain Cervical Cancer Test Market & Forecast
    9.3.2 Spain Pap Smear Test Market & Forecast
    9.3.3 Spain HPV DNA Test Market & Forecast

    10. Sweden – Cervical Cancer Test Analysis
     
    10.1 Sweden Cervical Cancer Test (Screening) Population
    10.1.1 Sweden Cervical Cancer Pap Smear Test Population & Forecast
    10.1.2 Sweden Cervical Cancer HPV DNA Test Population & Forecast

    10.2 Sweden Cervical Cancer Mortality

    10.3 Sweden Cervical Cancer Test (Screening) Market
    10.3.1 Sweden Cervical Cancer Test Market & Forecast
    10.3.2 Sweden Pap Smear Test Market & Forecast
    10.3.3 Sweden HPV DNA Test Market & Forecast

    11. Switzerland – Cervical Cancer Test Analysis
     
    11.1 Switzerland Cervical Cancer Test (Screening) Population
    11.1.1 Switzerland Cervical Cancer Pap Smear Test Population & Forecast
    11.1.2 Switzerland Cervical Cancer HPV DNA Test Population & Forecast

    11.2 Switzerland Cervical Cancer Mortality

    11.3 Switzerland Cervical Cancer Test (Screening) Market
    11.3.1 Switzerland Cervical Cancer Test Market & Forecast
    11.3.2 Switzerland Pap smear Test Market & Forecast
    11.3.3 Switzerland HPV DNA Test Market & Forecast

    12. Norway – Cervical Cancer Test Analysis
     
    12.1 Norway Cervical Cancer Test (Screening) Population
    12.1.1 Norway Cervical Cancer Pap Smear Test Population & Forecast
    12.1.2 Norway Cervical Cancer HPV DNA Test Population & Forecast

    12.2 Norway Cervical Cancer Mortality

    12.3 Norway Cervical Cancer Test (Screening) Market
    12.3.1 Norway Cervical Cancer Test Market & Forecast
    12.3.2 Norway Pap Smear Test Market & Forecast
    12.3.3 Norway HPV DNA Test Market & Forecast

    13. Netherlands – Cervical Cancer Test Analysis
     
    13.1 Netherlands Cervical Cancer Test (Screening) Population
    13.1.1 Netherlands Cervical Cancer Pap Smear Test Population & Forecast
    13.1.2 Netherlands Cervical Cancer HPV DNA Test Population & Forecast

    13.2 Netherlands Cervical Cancer Mortality

    13.3 Netherlands Cervical Cancer Test (Screening) Market
    13.3.1 Netherlands Cervical Cancer Test Market & Forecast
    13.3.2 Netherlands Pap Smear Test Market & Forecast
    13.3.3 Netherlands HPV DNA Test Market & Forecast

    14. United States – Cervical Cancer Test Analysis
     

    14.1 United States Cervical Cancer Test (Screening) Population
    14.1.1 United States Cervical Cancer Pap Smear Test Population & Forecast
    14.1.2 United States Cervical Cancer HPV DNA Test Population & Forecast

    14.2 United States Cervical Cancer Mortality

    14.3 United States Cervical Cancer Test (Screening) Market
    14.3.1 United States Cervical Cancer Test Market & Forecast
    14.3.2 United States Pap smear Test Market & Forecast
    14.3.3 United States HPV DNA Test Market & Forecast

    15. Canada – Cervical Cancer Test Analysis
     
    15.1 Canada Cervical Cancer Test (Screening) Population
    15.1.1 Canada Cervical Cancer Pap Smear Test Population & Forecast
    15.1.2 Canada Cervical Cancer HPV DNA Test Population & Forecast

    15.2 Canada Cervical Cancer Mortality

    15.3 Canada Cervical Cancer Test (Screening) Market
    15.3.1 Canada Cervical Cancer Test Market & Forecast
    15.3.2 Canada Pap Smear Test Market & Forecast
    15.3.3 Canada HPV DNA Test Market & Forecast

    16. Japan – Cervical Cancer Test Analysis
     
    16.1 Japan Cervical Cancer Test (Screening) Population
    16.1.1 Japan Cervical Cancer Pap Smear Test Population & Forecast
    16.1.2 Japan Cervical Cancer HPV DNA Test Population & Forecast

    16.2 Japan Cervical Cancer Mortality

    16.3 Japan Cervical Cancer Test (Screening) Market
    16.3.1 Japan Cervical Cancer Test Market & Forecast
    16.3.2 Japan Pap Smear Test Market & Forecast
    16.3.3 Japan HPV DNA Test Market & Forecast

    17. South Korea – Cervical Cancer Tests Analysis
     
    17.1 South Korea - Cervical Cancer Test (Screening) Population
    17.1.1 South Korea - Cervical Cancer Pap Smear Test Population & Forecast
    17.1.2 Korea Cervical Cancer HPV DNA Test Population & Forecast

    17.2 Korea Cervical Cancer Mortality

    17.3 Korea Cervical Cancer Test (Screening) Market
    17.3.1 Korea Cervical Cancer Test Market & Forecast
    17.3.2 Korea Pap Smear Test Market & Forecast
    17.3.3 Korea HPV DNA Test Market & Forecast

    18. Singapore – Cervical Cancer Tests Analysis
     
    18.1 Singapore - Cervical Cancer Test (Screening) Population
    18.1.1 Singapore - Cervical Cancer Pap Smear Test Population & Forecast
    18.1.2 Singapore Cervical Cancer HPV DNA Test Population & Forecast

    18.2 Singapore Cervical Cancer Test (Screening) Market
    18.2.1 Singapore Cervical Cancer Test Market & Forecast
    18.2.2 Singapore Pap Smear Test Market & Forecast
    18.2.3 Singapore HPV DNA Test Market & Forecast

    19. Malaysia – Cervical Cancer Test Analysis
     
    19.1 Malaysia - Cervical Cancer Test (Screening) Population
    19.1.1 Malaysia Cervical Cancer Pap Smear Test Population & Forecast
    19.1.2 Malaysia Cervical Cancer HPV DNA Test Population & Forecast

    19.2 Malaysia Cervical Cancer Test (Screening) Market
    19.2.1 Malaysia Cervical Cancer Test Market & Forecast
    19.2.2 Malaysia Pap Smear Test Market & Forecast
    19.2.3 Malaysia HPV DNA Test Market & Forecast

    20. Australia – Cervical Cancer Test Analysis
     
    20.1 Australia - Cervical Cancer Test (Screening) Population
    20.1.1 Australia Cervical Cancer Pap Smear Test Population & Forecast
    20.1.2 Australia Cervical Cancer HPV DNA Test Population & Forecast

    20.2 Australia Cervical Cancer Mortality

    20.3 Australia Cervical Cancer Test (Screening) Market
    20.3.1 Australia Cervical Cancer Test Market & Forecast
    20.3.2 Australia Pap Smear Test Market & Forecast
    20.3.3 Australia HPV DNA Test Market & Forecast

    21. India – Cervical Cancer Test Analysis
     
    21.1 India - Cervical Cancer Test (Screening) Population
    21.1.1 India Cervical Cancer Pap Smear Test Population & Forecast
    21.1.2 India Cervical Cancer HPV DNA Test Population & Forecast
    21.1.3 India Cervical Cancer VIA Test Population & Forecast

    21.2 India Cervical Cancer Test (Screening) Market
    21.2.1 India Cervical Cancer Test Market & Forecast
    21.2.2 India Pap Smear Test Market & Forecast
    21.2.3 India HPV DNA Test Market & Forecast
    21.2.4 India VIA Test Market & Forecast

    22. China – Cervical Cancer Test Analysis
     
    22.1 China - Cervical Cancer Test (Screening) Population
    22.1.1 China Cervical Cancer Pap smear Test Population & Forecast
    22.1.2 China Cervical Cancer HPV DNA Test Population & Forecast
    22.1.3 China Cervical Cancer VIA Test Population & Forecast

    22.2 China - Cervical Cancer Test (Screening) Market
    22.2.1 China Cervical Cancer Test Market & Forecast
    22.2.2 China Pap Smear Test Market & Forecast
    22.2.3 China HPV DNA Test Market & Forecast
    22.2.4 China VIA Test Market & Forecast

    23. Thailand – Cervical Cancer Test Analysis
     
    23.1 Thailand - Cervical Cancer Test (Screening) Population
    23.1.1 Thailand Cervical Cancer Pap Smear Test Population & Forecast
    23.1.2 Thailand Cervical Cancer VIA Test Population & Forecast

    23.2 Thailand Cervical Cancer Test (Screening) Market
    23.2.1 Thailand Cervical Cancer Test Market & Forecast
    23.2.2 Thailand Pap smear Test Market & Forecast
    23.2.3 Thailand VIA Test Market & Forecast

    24. Indonesia – Cervical Cancer Test Analysis
     
    24.1 Indonesia Cervical Cancer Test (Screening) Population
    24.1.1 Indonesia Cervical Cancer Pap Smear Test Population & Forecast
    24.1.2 Indonesia Cervical Cancer HPV DNA Test Population & Forecast
    24.1.3 Indonesia Cervical Cancer VIA Test Population & Forecast
    24.1.4 Indonesia Cervical Cancer Both (Pap Smear & VIA) Test Population & Forecast

    24.2 Indonesia Cervical Cancer Test (Screening) Market
    24.2.1 Indonesia Cervical Cancer Test Market & Forecast
    24.2.2 Indonesia Pap smear Test Market & Forecast
    24.2.3 Indonesia HPV DNA Test Market & Forecast
    24.2.4 Indonesia VIA Test Market & Forecast
    24.2.5 Indonesia Cervical Cancer Both (Pap Smear & VIA) Test Market & Forecast

    25. Cervical Cancer Test Market Growth Drivers
    25.1 Point No. 1
    25.2 Point No. 2
    25.3 Point No. 3

    26. Challenges in Cervical Cancer Test Market
    26.1 Point No. 1
    26.2 Point No. 2

     

    List of Figures:

    Figure 2 1: Worldwide – Cervical Cancer Test Population (Million), 2005 – 2013
    Figure 2 2: Worldwide – Forecast for Cervical Cancer Test Population (Million), 2014 – 2020

    Figure 3 1: Worldwide – Cervical Cancer Test Market (Million US$), 2005 – 2013
    Figure 3 2: Worldwide – Forecast for Cervical Cancer Test Market (Million US$), 2014 – 2020
    Figure 3 3: Worldwide – Cervical Cancer Pap Smear Test Market (Million US$), 2005 – 2013
    Figure 3 4: Worldwide – Forecast for Cervical Cancer Pap Smear Test Market (Million US$), 2014 – 2020
    Figure 3 5: Worldwide – Cervical Cancer HPV DNA Test Market (Million US$), 2005 – 2013
    Figure 3 6: Worldwide – Forecast for Cervical Cancer HPV DNA Test Market (Million US$), 2014 – 2020
    Figure 3 7: Worldwide – Cervical Cancer VIA Test Market (Million US$), 2005 – 2013
    Figure 3 8: Worldwide – Forecast for Cervical Cancer VIA Test Market (Million US$), 2014 – 2020

    Figure 5 1: United Kingdom – Cervical Cancer Pap Smear Test Population (Thousand), 2005 – 2013
    Figure 5 2: United Kingdom – Forecast for Cervical Cancer Pap Smear Test Population (Thousand), 2014 – 2020
    Figure 5 3: United Kingdom – Cervical Cancer HPV DNA Test Population (Thousand), 2005 – 2013
    Figure 5 4: United Kingdom – Forecast for Cervical Cancer HPV DNA Test Population (Thousand), 2014 – 2020
    Figure 5 5: United Kingdom – Cervical Cancer Mortality (Number), 2001 – 2011
    Figure 5 6: United Kingdom – Cervical Cancer Test Market (Million US$), 2005 – 2013
    Figure 5 7: United Kingdom – Forecast for Cervical Cancer Test Market (Million US$), 2014 – 2020
    Figure 5 8: United Kingdom – Pap Smear Test Market (Million US$), 2005 – 2013
    Figure 5 9: United Kingdom – Forecast for Pap Smear Test Market (Million US$), 2014 – 2020
    Figure 5 10: United Kingdom – HPV DNA Test Market (Million US$), 2005 – 2013
    Figure 5 11: United Kingdom – Forecast for HPV DNA Test Market (Million US$), 2014 – 2020

    Figure 6 1: France – Cervical Cancer Pap Smear Test Population (Thousand), 2005 – 2013
    Figure 6 2: France – Forecast for Cervical Cancer Pap Smear Test Population (Thousand), 2014 – 2020
    Figure 6 3: France – Cervical Cancer HPV DNA Test Population (Thousand), 2005 – 2013
    Figure 6 4: France – Forecast for Cervical Cancer HPV DNA Test Population (Thousand), 2014 – 2020
    Figure 6 5: France – Cervical Cancer Mortality (Number), 2001 – 2011
    Figure 6 6: France – Cervical Cancer Test Market (Million US$), 2005 – 2013
    Figure 6 7: France – Forecast for Cervical Cancer Test Market (Million US$), 2014 – 2020
    Figure 6 8: France – Pap Smear Test Market (Million US$), 2005 – 2013
    Figure 6 9: France – Forecast for Pap Smear Test Market (Million US$), 2014 – 2020
    Figure 6 10: France – HPV DNA Test Market (Million US$), 2005 – 2013
    Figure 6 11: France – Forecast for HPV DNA Test Market (Million US$), 2014 – 2020

    Figure 7 1: Germany – Cervical Cancer Pap Smear Test Population (Thousand), 2005 – 2013
    Figure 7 2: Germany – Forecast for Cervical Cancer Pap Smear Test Population (Thousand), 2014 – 2020
    Figure 7 3: Germany – Cervical Cancer HPV DNA Test Population (Thousand), 2005 – 2013
    Figure 7 4: Germany – Forecast for Cervical Cancer HPV DNA Test Population (Thousand), 2014 – 2020
    Figure 7 5: Germany – Cervical Cancer Mortality (Number), 2001 – 2011
    Figure 7 6: Germany – Cervical Cancer Test Market (Million US$), 2005 – 2013
    Figure 7 7: Germany – Forecast for Cervical Cancer Test Market (Million US$), 2014 – 2020
    Figure 7 8: Germany – Pap Smear Test Market (Million US$), 2005 – 2013
    Figure 7 9: Germany – Forecast for Pap Smear Test Market (Million US$), 2014 – 2020
    Figure 7 10: Germany – HPV DNA Test Market (Million US$), 2005 – 2013
    Figure 7 11: Germany – Forecast for HPV DNA Test Market (Million US$), 2014 – 2020

    Figure 8 1: Italy – Cervical Cancer Pap Smear Test Population (Thousand), 2005 – 2013
    Figure 8 2: Italy – Forecast for Cervical Cancer Pap Smear Test Population (Thousand), 2014 – 2020
    Figure 8 3: Italy – Cervical Cancer HPV DNA Test Population (Thousand), 2005 – 2013
    Figure 8 4: Italy – Forecast for Cervical Cancer HPV DNA Test Population (Thousand), 2014 – 2020
    Figure 8 5: Italy – Cervical Cancer Mortality (Number), 2001 – 2011
    Figure 8 6: Italy – Cervical Cancer Test Market (Million US$), 2005 – 2013
    Figure 8 7: Italy – Forecast for Cervical Cancer Test Market (Million US$), 2014 – 2020
    Figure 8 8: Italy – Pap Smear Test Market (Million US$), 2005 – 2013
    Figure 8 9: Italy – Forecast for Pap Smear Test Market (Million US$), 2014 – 2020
    Figure 8 10: Italy – HPV DNA Test Market (Million US$), 2005 – 2013
    Figure 8 11: Italy – Forecast for HPV DNA Test Market (Million US$), 2014 – 2020

    Figure 9 1: Spain – Cervical Cancer Pap Smear Test Population (Thousand), 2005 – 2013
    Figure 9 2: Spain – Forecast for Cervical Cancer Pap Smear Test Population (Thousand), 2014 – 2020
    Figure 9 3: Spain – Cervical Cancer HPV DNA Test Population (Thousand), 2005 – 2013
    Figure 9 4: Spain – Forecast for Cervical Cancer HPV DNA Test Population (Thousand), 2014 –2020
    Figure 9 5: Spain – Cervical Cancer Mortality (Number), 2001 – 2011
    Figure 9 6: Spain – Cervical Cancer Test Market (Million US$), 2005 – 2013
    Figure 9 7: Spain – Forecast for Cervical Cancer Test Market (Million US$), 2014 – 2020
    Figure 9 8: Spain – Pap Smear Test Market (Million US$), 2005 – 2013
    Figure 9 9: Spain – Forecast for Pap Smear Test Market (Million US$), 2014 – 2020
    Figure 9 10: Spain – HPV DNA Test Market (Million US$), 2005 – 2013
    Figure 9 11: Spain – Forecast for HPV DNA Test Market (Million US$), 2014 – 2020

    Figure 10 1: Sweden – Cervical Cancer Pap Smear Test Population (Thousand), 2005 – 2013
    Figure 10 2: Sweden – Forecast for Cervical Cancer Pap Smear Test Population (Thousand), 2014 – 2020
    Figure 10 3: Sweden – Cervical Cancer HPV DNA Test Population (Thousand), 2005 – 2013
    Figure 10 4: Sweden – Forecast for Cervical Cancer HPV DNA Test Population (Thousand), 2014 – 2020
    Figure 10 5: Sweden – Cervical Cancer Mortality (Number), 2001 – 2011
    Figure 10 6: Sweden – Cervical Cancer Test Market (Million US$), 2005 – 2013
    Figure 10 7: Sweden – Forecast for Cervical Cancer Test Market (Million US$), 2014 – 2020
    Figure 10 8: Sweden – Pap Smear Test Market (Million US$), 2005 – 2013
    Figure 10 9: Sweden – Forecast for Pap Smear Test Market (Million US$), 2014 – 2020
    Figure 10 10: Sweden – HPV DNA Test Market (Million US$), 2005 – 2013
    Figure 10 11: Sweden – Forecast for HPV DNA Test Market (Million US$), 2014 – 2020

    Figure 11 1: Switzerland – Cervical Cancer Pap Smear Test Population (Thousand), 2005 – 2013
    Figure 11 2: Switzerland – Forecast for Cervical Cancer Pap Smear Test Population (Thousand), 2014 – 2020
    Figure 11 3: Switzerland – Cervical Cancer HPV DNA Test Population (Thousand), 2005 – 2013
    Figure 11 4: Switzerland – Forecast for Cervical Cancer HPV DNA Test Population (Thousand), 2014 – 2020
    Figure 11 5: Switzerland – Cervical Cancer Mortality (Number), 2001 – 2011
    Figure 11 6: Switzerland – Cervical Cancer Test Market (Million US$), 2005 – 2013
    Figure 11 7: Switzerland – Forecast for Cervical Cancer Test Market (Million US$), 2014 – 2020
    Figure 11 8: Switzerland – Pap Smear Test Market (Million US$), 2005 – 2013
    Figure 11 9: Switzerland – Forecast for Pap Smear Test Market (Million US$), 2014 – 2020
    Figure 11 10: Switzerland – HPV DNA Test Market (Million US$), 2005 – 2013
    Figure 11 11: Switzerland – Forecast for HPV DNA Test Market (Million US$), 2014 – 2020

    Figure 12 1: Norway – Cervical Cancer Pap Smear Test Population (Thousand), 2005 – 2013
    Figure 12 2: Norway – Forecast for Cervical Cancer Pap Smear Test Population (Thousand), 2014 – 2020
    Figure 12 3: Norway – Cervical Cancer HPV DNA Test Population (Thousand), 2005 – 2013
    Figure 12 4: Norway – Forecast for Cervical Cancer HPV DNA Test Population (Thousand), 2014 – 2020
    Figure 12 5: Norway – Cervical Cancer Mortality (Number), 2001 – 2011
    Figure 12 6: Norway – Cervical Cancer Test Market (Million US$), 2005 – 2013
    Figure 12 7: Norway – Forecast for Cervical Cancer Test Market (Million US$), 2014 – 2020
    Figure 12 8: Norway – Pap Smear Test Market (Million US$), 2005 – 2013
    Figure 12 9: Norway – Forecast for Pap Smear Test Market (Million US$), 2014 – 2020
    Figure 12 10: Norway – HPV DNA Test Market (Million US$), 2005 – 2013
    Figure 12 11: Norway – Forecast for HPV DNA Test Market (Million US$), 2014 – 2020

    Figure 13 1: Netherlands – Cervical Cancer Pap Smear Test Population (Thousand), 2005 – 2013
    Figure 13 2: Netherlands – Forecast for Cervical Cancer Pap Smear Test Population (Thousand), 2014 – 2020
    Figure 13 3: Netherlands – Cervical Cancer HPV DNA Test Population (Thousand), 2005 – 2013
    Figure 13 4: Netherlands – Forecast for Cervical Cancer HPV DNA Test Population (Thousand), 2014 – 2020
    Figure 13 5: Netherlands – Cervical Cancer Mortality (Number), 2001 – 2011
    Figure 13 6: Netherlands – Cervical Cancer Test Market (Million US$), 2005 – 2013
    Figure 13 7: Netherlands – Forecast for Cervical Cancer Test Market (Million US$), 2014 – 2020
    Figure 13 8: Netherlands – Pap Smear Test Market (Million US$), 2005 – 2013
    Figure 13 9: Netherlands – Forecast for Pap Smear Test Market (Million US$), 2014 – 2020
    Figure 13 10: Netherlands – HPV DNA Test Market (Million US$), 2005 – 2013
    Figure 13 11: Netherlands – Forecast for HPV DNA Test Market (Million US$), 2014 – 2020

    Figure 14 1: United States – Cervical Cancer Pap Smear Test Population (Thousand), 2005 – 2013
    Figure 14 2: United States – Forecast for Cervical Cancer Pap Smear Test Population (Thousand), 2014 – 2020
    Figure 14 3: United States – Cervical Cancer HPV DNA Test Population (Thousand), 2005 – 2013
    Figure 14 4: United States – Forecast for Cervical Cancer HPV DNA Test Population (Thousand), 2014 – 2020
    Figure 14 5: United States – Cervical Cancer Mortality (Number), 2001 – 2011
    Figure 14 6: United States – Cervical Cancer Test Market (Million US$), 2005 – 2013
    Figure 14 7: United States – Forecast for Cervical Cancer Test Market (Million US$), 2014 – 2020
    Figure 14 8: United States – Pap smear Test Market (Million US$), 2005 – 2013
    Figure 14 9: United States – Forecast for Pap Smear Test Market (Million US$), 2014 – 2020
    Figure 14 10: United States – HPV DNA Test Market (Million US$), 2005 – 2013
    Figure 14 11: United States – Forecast for HPV DNA Test Market (Million US$), 2014 – 2020

    Figure 15 1: Canada – Cervical Cancer Pap Smear Test Population (Thousand), 2005 – 2013
    Figure 15 2: Canada – Forecast for Cervical Cancer Pap Smear Test Population (Thousand), 2014 – 2020
    Figure 15 3: Canada – Cervical Cancer HPV DNA Test Population (Thousand), 2005 – 2013
    Figure 15 4: Canada – Forecast for Cervical Cancer HPV DNA Test Population (Thousand), 2014 – 2020
    Figure 15 5: Canada – Cervical Cancer Mortality (Number), 2001 – 2011
    Figure 15 6: Canada – Cervical Cancer Test Market (Million US$), 2005 – 2013
    Figure 15 7: Canada – Forecast for Cervical Cancer Test Market (Million US$), 2014 – 2020
    Figure 15 8: Canada – Pap Smear Test Market (Million US$), 2005 – 2013
    Figure 15 9: Canada – Forecast for Pap Smear Test Market (Million US$), 2014 – 2020
    Figure 15 10: Canada – HPV DNA Test Market (Million US$), 2005 – 2013
    Figure 15 11: Canada – Forecast for HPV DNA Test Market (Million US$), 2014 – 2020

    Figure 16 1: Japan – Cervical Cancer Pap Smear Test Population (Thousand), 2005 – 2013
    Figure 16 2: Japan – Forecast for Cervical Cancer Pap Smear Test Population (Thousand), 2014 – 2020
    Figure 16 3: Japan – Cervical Cancer HPV DNA Test Population (Thousand), 2005 – 2013
    Figure 16 4: Japan – Forecast for Cervical Cancer HPV DNA Test Population (Thousand), 2014 – 2020
    Figure 16 5: Japan – Cervical Cancer Mortality (Number), 2001 – 2011
    Figure 16 6: Japan – Cervical Cancer Test Market (Million US$), 2005 – 2013
    Figure 16 7: Japan – Forecast for Cervical Cancer Test Market (Million US$), 2014 – 2020
    Figure 16 8: Japan – Pap Smear Test Market (Million US$), 2005 – 2013
    Figure 16 9: Japan – Forecast for Pap Smear Test Market (Million US$), 2014 – 2020
    Figure 16 10: Japan – HPV DNA Test Market (Million US$), 2005 – 2013
    Figure 16 11: Japan – Forecast for HPV DNA Test Market (Million US$), 2014 – 2020

    Figure 17 1: Korea – Cervical Cancer Pap Smear Test Population (Thousand), 2005 – 2013
    Figure 17 2: Korea – Forecast for Cervical Cancer Pap Smear Test Population (Thousand), 2014 – 2020
    Figure 17 3: Korea – Cervical Cancer HPV DNA Test Population (Thousand), 2005 – 2013
    Figure 17 4: Korea – Forecast for Cervical Cancer HPV DNA Test Population (Thousand), 2014 – 2020
    Figure 17 5: Korea – Cervical Cancer Mortality (Number), 2001 – 2011
    Figure 17 6: Korea – Cervical Cancer Test Market (Million US$), 2005 – 2013
    Figure 17 7: Korea – Forecast for Cervical Cancer Test Market (Million US$), 2014 – 2020
    Figure 17 8: Korea – Pap Smear Test Market (Million US$), 2005 – 2013
    Figure 17 9: Korea – Forecast for Pap Smear Test Market (Million US$), 2014 – 2020
    Figure 17 10: Korea – HPV DNA Test Market (Million US$), 2005 – 2013
    Figure 17 11: Korea – Forecast for HPV DNA Test Market (Million US$), 2014 – 2020

    Figure 18 1: Singapore – Cervical Cancer Pap Smear Test Population (Thousand), 2005 – 2013
    Figure 18 2: Singapore – Forecast for Cervical Cancer Pap Smear Test Population (Thousand), 2014 – 2020
    Figure 18 3: Singapore – Cervical Cancer HPV DNA Test Population (Thousand), 2005 – 2013
    Figure 18 4: Singapore – Forecast for Cervical Cancer HPV DNA Test Population (Thousand), 2014 – 2020
    Figure 18 5: Singapore – Cervical Cancer Test Market (Million US$), 2005 – 2013
    Figure 18 6: Singapore – Forecast for Cervical Cancer Test Market (Million US$), 2014 – 2020
    Figure 18 7: Singapore – Pap Smear Test Market (Million US$), 2005 – 2013
    Figure 18 8: Singapore – Forecast for Pap Smear Test Market (Million US$), 2014 – 2020
    Figure 18 9: Singapore – HPV DNA Test Market (Million US$), 2005 – 2013
    Figure 18 10: Singapore – Forecast for HPV DNA Test Market (Million US$), 2014 – 2020

    Figure 19 1: Malaysia – Cervical Cancer Pap Smear Test Population (Thousand), 2005 – 2013
    Figure 19 2: Malaysia – Forecast for Cervical Cancer Pap Smear Test Population (Thousand), 2014 – 2020
    Figure 19 3: Malaysia – Cervical Cancer HPV DNA Test Population (Thousand), 2005 – 2013
    Figure 19 4: Malaysia – Forecast for Cervical Cancer HPV DNA Test Population (Thousand), 2014 – 2020
    Figure 19 5: Malaysia – Cervical Cancer Test Market (Million US$), 2005 – 2013
    Figure 19 6: Malaysia – Forecast for Cervical Cancer Test Market (Million US$), 2014 – 2020
    Figure 19 7: Malaysia – Pap smear Test Market (Million US$), 2005 – 2013
    Figure 19 8: Malaysia – Forecast for Pap smear Test Market (Million US$), 2014 – 2020
    Figure 19 9: Malaysia – HPV DNA Test Market (Million US$), 2005 – 2013
    Figure 19 10: Malaysia – Forecast for HPV DNA Test Market (Million US$), 2014 – 2020

    Figure 20 1: Australia – Cervical Cancer Pap Smear Test Population (Thousand), 2005 – 2013
    Figure 20 2: Australia – Forecast for Cervical Cancer Pap Smear Test Population (Thousand), 2014 – 2020
    Figure 20 3: Australia – Cervical Cancer HPV DNA Test Population (Thousand), 2005 – 2013
    Figure 20 4: Australia – Forecast for Cervical Cancer HPV DNA Test Population (Thousand), 2014 – 2020
    Figure 20 5: Australia – Cervical Cancer Mortality (Number), 2001 – 2011
    Figure 20 6: Australia – Cervical Cancer Test Market (Million US$), 2005 – 2013
    Figure 20 7: Australia – Forecast for Cervical Cancer Test Market (Million US$), 2014 – 2020
    Figure 20 8: Australia – Pap Smear Test Market (Million US$), 2005 – 2013
    Figure 20 9: Australia – Forecast for Pap Smear Test Market (Million US$), 2014 – 2020
    Figure 20 10: Australia – HPV DNA Test Market (Million US$), 2005 – 2013
    Figure 20 11: Australia – Forecast for HPV DNA Test Market (Million US$), 2014 – 2020

    Figure 21 1: India – Cervical Cancer Pap Smear Test Population (Thousand), 2005 – 2013
    Figure 21 2: India – Forecast for Cervical Cancer Pap Smear Test Population (Thousand), 2014 – 2020
    Figure 21 3: India – Cervical Cancer HPV DNA Test Population (Thousand), 2005 – 2013
    Figure 21 4: India – Forecast for Cervical Cancer HPV DNA Test Population (Thousand), 2014 – 2020
    Figure 21 5: India – Cervical Cancer VIA Test Population (Thousand), 2005 – 2013
    Figure 21 6: India – Forecast for Cervical Cancer VIA Test Population (Thousand), 2014 – 2020
    Figure 21 7: India – Cervical Cancer Test Market (Million US$), 2005 – 2013
    Figure 21 8: India – Forecast for Cervical Cancer Test Market (Million US$), 2014 – 2020
    Figure 21 9: India – Pap smear Test Market (Million US$), 2005 – 2013
    Figure 21 10: India – Forecast for Pap smear Test Market (Million US$), 2014 – 2020
    Figure 21 11: India – HPV DNA Test Market (Million US$), 2005 – 2013
    Figure 21 12: India – Forecast for HPV DNA Test Market (Million US$), 2014 – 2020
    Figure 21 13: India – VIA Test Market (Million US$), 2005 – 2013
    Figure 21 14: India – Forecast for VIA Test Market (Million US$), 2014 – 2020

    Figure 22 1: China – Cervical Cancer Pap Smear Test Population (Thousand), 2005 – 2013
    Figure 22 2: China – Forecast for Cervical Cancer Pap Smear Test Population (Thousand), 2014 – 2020
    Figure 22 3: China – Cervical Cancer HPV DNA Test Population (Thousand), 2005 – 2013
    Figure 22 4: China – Forecast for Cervical Cancer HPV DNA Test Population (Thousand), 2014 – 2020
    Figure 22 5: China – Cervical Cancer VIA Test Population (Thousand), 2005 – 2013
    Figure 22 6: China – Forecast for Cervical Cancer VIA Test Population (Thousand), 2014 – 2020
    Figure 22 7: China – Cervical Cancer Test Market (Million US$), 2005 – 2013
    Figure 22 8: China – Forecast for Cervical Cancer Test Market (Million US$), 2014 – 2020
    Figure 22 9: China – Pap smear Test Market (Million US$), 2005 – 2013
    Figure 22 10: China – Forecast for Pap Smear Test Market (Million US$), 2014 – 2020
    Figure 22 11: China – HPV DNA Test Market (Million US$), 2005 – 2013
    Figure 22 12: China – Forecast for HPV DNA Test Market (Million US$), 2014 – 2020
    Figure 22 13: China – VIA Test Market (Million US$), 2005 – 2013
    Figure 22 14: China – Forecast for VIA Test Market (Million US$), 2014 – 2020

    Figure 23 1: Thailand – Cervical Cancer Pap Smear Test Population (Thousand), 2005 – 2013
    Figure 23 2: Thailand – Forecast for Cervical Cancer Pap Smear Test Population (Thousand), 2014 – 2020
    Figure 23 3: Thailand – Cervical Cancer VIA Test Population (Thousand), 2005 – 2013
    Figure 23 4: Thailand – Forecast for Cervical Cancer VIA Test Population (Thousand), 2014 – 2020
    Figure 23 5: Thailand – Cervical Cancer Test Market (Million US$), 2005 – 2013
    Figure 23 6: Thailand – Forecast for Cervical Cancer Test Market (Million US$), 2014 – 2020
    Figure 23 7: Thailand – Pap smear Test Market (Million US$), 2005 – 2013
    Figure 23 8: Thailand – Forecast for Pap Smear Test Market (Million US$), 2014 – 2020
    Figure 23 9: Thailand – VIA Test Market (Million US$), 2005 – 2013
    Figure 23 10: Thailand – Forecast for VIA Test Market (Million US$), 2014 – 2020

    Figure 24 1: Indonesia – Cervical Cancer Pap Smear Test Population (Thousand), 2005 – 2013
    Figure 24 2: Indonesia – Forecast for Cervical Cancer Pap Smear Test Population (Thousand), 2014 – 2020
    Figure 24 3: Indonesia – Cervical Cancer HPV DNA Test Population (Thousand), 2005 – 2013
    Figure 24 4: Indonesia – Forecast for Cervical Cancer HPV DNA Test Population (Thousand), 2014 – 2020
    Figure 24 5: Indonesia – Cervical Cancer VIA Test Population (Thousand), 2005 – 2013
    Figure 24 6: Indonesia – Forecast for Cervical Cancer VIA Test Population (Thousand), 2014 – 2020
    Figure 24 7: Indonesia – Cervical Cancer Both (Pap Smear & VIA) Test Population (Thousand), 2005 – 2013
    Figure 24 8: Indonesia – Forecast for Cervical Cancer Both (Pap Smear & VIA) Test Population (Thousand), 2014 – 2020
    Figure 24 9: Indonesia – Cervical Cancer Test Market (Million US$), 2005 – 2013
    Figure 24 10: Indonesia – Forecast for Cervical Cancer Test Market (Million US$), 2014 – 2020
    Figure 24 11: Indonesia – Pap Smear Test Market (Million US$), 2005 – 2013
    Figure 24 12: Indonesia – Forecast for Pap Smear Test Market (Million US$), 2014 – 2020
    Figure 24 13: Indonesia – HPV DNA Test Market (Million US$), 2005 – 2013
    Figure 24 14: Indonesia – Forecast for HPV DNA Test Market (Million US$), 2014 – 2020
    Figure 24 15: Indonesia – VIA Test Market (Million US$), 2005 – 2013
    Figure 24 16: Indonesia – Forecast for VIA Test Market (Million US$), 2014 – 2020
    Figure 24 17: Indonesia – Both (Pap smear & VIA) Test Market (Million US$), 2005 – 2013
    Figure 24 18: Indonesia – Forecast for Both (Pap Smear & VIA) Test Market (Million US$), 2014 – 2020

    List of Tables:

    Table 4 1: Worldwide – Cervical Cancer Test Population Share (Percent), 2005 – 2013
    Table 4 2: Worldwide – Forecast for Cervical Cancer Test Population Share (Percent), 2014 – 2020
    Table 4 3: Worldwide – Cervical Cancer Test Market Share (Percent), 2005 – 2013
    Table 4 4: Worldwide – Forecast for Cervical Cancer Test Market Share (Percent), 2014 – 2020
    Table 4 5: Worldwide – Cervical Cancer Pap Smear Test Market Share (Percent), 2005 – 2013
    Table 4 6: Worldwide – Forecast for Cervical Cancer Pap Smear Test Market Share (Percent), 2014 – 2020
    Table 4 7: Worldwide – Cervical Cancer HPV DNA Test Market Share (Percent), 2005 – 2013
    Table 4 8: Worldwide – Forecast for Cervical Cancer HPV DNA Test Market Share (Percent), 2014 – 2020
    Table 4 9: Worldwide – Cervical Cancer VIA Test Market Share (Percent), 2005 – 2013
    Table 4 10: Worldwide – Forecast for Cervical Cancer VIA Test Market Share (Percent), 2014 – 2020

    Table 25 1: Worldwide – List of Countries which offer VIA Test via National Programs, 2010
    Table 25 2: Worldwide – List of Countries which offer VIA Test via Pilot Programs, 2010
    Table 25 3: Worldwide – Prevalence (Percent) of Young Women (15–44 Years) who Have Sex before the Age of 15 Years, 1994 – 2006
    Table 25 4: Worldwide – HPV Prevalence (Percent) among Women with Normal Cervical Cytology, 2010

    Related Reports

    • Global Prostate Cancer Therapeutics Market to 2020

      Renub Research report titled "Global Prostate Cancer Therapeutics Market to 2020" provides a comprehensive assessment of the fast-evolving, high-growth of Prostate Cancer Therapeutics Market. This 80 page report with 35 Figures and 2 Tables analyses the Prostate Cancer Therapy Drugs Market, driving factors and challenges for prostate cancer market landscape....

      Price: $1,200.00
    • Colposcopy Test, Market, Users & Forecast - Asia & Middle East Analysis

      Colposcopy test market for Asia and Middle East is expected to be close to US$ 2 Billion by 2020. Japan is the leading player in Asia & Middle East Colposcopy test market. Japan and China are only two players who have double digit market share percent in Colposcopy Test Market. Saudi Arabia is having highest market share in Middle East. It is predicted that Malaysia will replace Thailand to capture the 3rd spot during the forecasting period 2015 to 2020. ...

      Price: $1,200.00